<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847262</url>
  </required_header>
  <id_info>
    <org_study_id>HOT-2</org_study_id>
    <nct_id>NCT00847262</nct_id>
  </id_info>
  <brief_title>Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes</brief_title>
  <acronym>HOT-DM</acronym>
  <official_title>Hypertension With Obesity Trial: Diabetes Mellitus Branch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have shown that obese people are more prone to high blood pressure. With the&#xD;
      co-existence of obesity, hypertension and diabetes, patients were more susceptible to&#xD;
      hyperlipidemia, coronary and cerebral atherosclerosis and peripheral vascular disease.&#xD;
      Abdominal obesity has often accompanied by substantial accumulation of visceral fat, which&#xD;
      increased secretion of many inflammatory mediators, cytokines and adipocytokines and played&#xD;
      an important role in cardiovascular and metabolic disease. Some reports had shown that&#xD;
      angiotensin II receptor blockers (ARB) may improve metabolic profiles in patients with&#xD;
      diabetes or metabolic syndrome, in addition to its hypotensive effect. It has been reported&#xD;
      that some ARB, such as telmisartan and candesartan, can prevent weight gain and&#xD;
      high-fat-induced obesity in experimental animals. However, whether telmisartan intervention&#xD;
      on improvement of fat deposition and other related metabolic profiles is better than a CCB&#xD;
      drugs (amlodipine) in those obese hypertensive patients with diabetes, was still unknown.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic profiles, including lipid profile and blood glucose</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal fat assessed by CT</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity parameters, including waist circumference (WC) and body mass index (BMI)</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of side effects between groups</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hypertension</condition>
  <condition>Obesity</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Telmisartan Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine intervention group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temisartan</intervention_name>
    <description>Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day</description>
    <arm_group_label>Telmisartan Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day</description>
    <arm_group_label>Amlodipine Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Information Consent Signed&#xD;
&#xD;
          -  Aged 30~70 years&#xD;
&#xD;
          -  For whom without anti-hypertensive therapy in 2&#xD;
             weeks：140mmHg≤SBP&lt;180mmHg，或90mmHg≤DBP&lt;110mmHg. For whom with anti-hypertensive&#xD;
             therapies in 2 weeks：SBP&lt;180mmHg, 且DBP&lt;110mmHg&#xD;
&#xD;
          -  Waist circumference higher than 90cm in men, 80cm in women&#xD;
&#xD;
          -  Diagnosed diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Grade 3 hypertension: SBP≥180mmHg, or DBP≥110mmHg&#xD;
&#xD;
          -  Waist circumference less than 90cm in men, 80cm in women&#xD;
&#xD;
          -  Known allergy or hypersensitivity to trial drugs&#xD;
&#xD;
          -  NYHA grade Ⅱ~Ⅳ heart failure, Myocardial infarction or cerebrovascular accident in 1&#xD;
             year preceding the trial&#xD;
&#xD;
          -  Acute infections, tumor, severe arrhythmia, mental disease, drug or alcohol abuse&#xD;
&#xD;
          -  History of hepatitis or cirrhosis&#xD;
&#xD;
          -  History of severe kidney disease&#xD;
&#xD;
          -  Pregnant, lactation&#xD;
&#xD;
          -  Enrolled in other trials in 3 months&#xD;
&#xD;
          -  Any obstacles of follow-up or compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiming Zhu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The third hospital affiliated to the Third Military Medical University. China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The third hospital affiliated to the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>December 15, 2013</last_update_submitted>
  <last_update_submitted_qc>December 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhiming Zhu</investigator_full_name>
    <investigator_title>Chief of the Department of Hypertension &amp; Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Abdominal obesity</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

